rs140387675
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_000057.4(BLM):c.3427G>A(p.Glu1143Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000905 in 1,613,766 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000057.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152122Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000107 AC: 27AN: 251310Hom.: 0 AF XY: 0.0000957 AC XY: 13AN XY: 135828
GnomAD4 exome AF: 0.0000930 AC: 136AN: 1461644Hom.: 0 Cov.: 31 AF XY: 0.0000839 AC XY: 61AN XY: 727076
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152122Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74300
ClinVar
Submissions by phenotype
Bloom syndrome Uncertain:5
- -
- -
- -
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1143 of the BLM protein (p.Glu1143Lys). This variant is present in population databases (rs140387675, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of BLM-related conditions (PMID: 30262796, 35957908). ClinVar contains an entry for this variant (Variation ID: 127499). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BLM protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect BLM function (PMID: 23129629). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not provided Uncertain:3Benign:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate: sensitivity to hydroxyurea similar to wildtype, suggesting no significant impact on helicase activity (PMID: 23129629); Observed in individuals with a personal or family history including colorectal and breast and/or ovarian cancer (PMID: 30262796, 31159747, 32449991, 35264596, 35957908); This variant is associated with the following publications: (PMID: 32449991, 30262796, 31159747, 27516001, 33528079, 23129629, 35264596, 28944238, 35957908) -
- -
- -
- -
not specified Uncertain:2
DNA sequence analysis of the BLM gene demonstrated a sequence change, c.3427G>A, in exon 18 that results in an amino acid change, p.Glu1143Lys. This sequence change has been described in gnomAD with a frequency of 0.02% in the East Asian sub-population (dbSNP rs140387675). The p.Glu1143Lys change affects a moderately conserved amino acid residue located in a domain of the BLM protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Glu1143Lys substitution. This sequence change does not appear to have been previously described in patients with BLM-related disorders. Due to the lack of sufficient evidences, the clinical significance of the p.Glu1143Lys change remains unknown at this time. -
Variant summary: BLM c.3427G>A (p.Glu1143Lys) results in a conservative amino acid change located in the RQC domain (IPR018982) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 251310 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in BLM causing Bloom Syndrome (0.00011 vs 0.0035), allowing no conclusion about variant significance. c.3427G>A has been reported in the literature in the heterozygous state in individuals affected with colorectal cancer, breast and/or ovarian cancer, pancreatic cancer, and epilepsy (e.g. Tian_2021, Gifoni_2022, Quezada Urban_2018, Guindalini_2022, Atli_2022, Emelyanova_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Bloom Syndrome. At least one publication reports experimental evidence evaluating an impact on protein function. These results showed no damaging effect of this variant (Mirzaei_2012). The following publications have been ascertained in the context of this evaluation (PMID: 33528079, 35309086, 35957908, 35264596, 23129629, 30262796, 34512202). ClinVar contains an entry for this variant (Variation ID: 127499). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.E1143K variant (also known as c.3427G>A), located in coding exon 17 of the BLM gene, results from a G to A substitution at nucleotide position 3427. The glutamic acid at codon 1143 is replaced by lysine, an amino acid with similar properties. This alteration did not show hypersensitivity to the DNA damaging agent hydroxyurea, as compared to the wild-type allele, in a humanized yeast model (Mirzaei H et al. Proc. Natl. Acad. Sci. U.S.A. 2012 Nov;109:19357-62). This alteration has been reported in an individual with a personal history of five primary malignant cancers and a family history consistent with Li Fraumeni syndrome, who was identified to carry TP53 p.R175H (Zampiga V et al. Int J Biol Markers, 2016 Dec;31:e461-e465). This variant has also been reported in multiple cohorts undergoing evaluation for inherited cancer predisposition (DeRycke MS et al. Mol Genet Genomic Med, 2017 Sep;5:553-569; Quezada Urban R et al. Cancers (Basel), 2018 Sep;10:; Tsaousis GN et al. BMC Cancer, 2019 Jun;19:535; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at